Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer
Rainer Albert(Novartis (Switzerland)), Klaus Hinterding(Novartis Institutes for BioMedical Research), Volker Brinkmann(Novartis Institutes for BioMedical Research), Danilo Guerini(Novartis Institutes for BioMedical Research), Constanze Müller-Hartwieg(Novartis Institutes for BioMedical Research), Helmut Knecht(Novartis (Switzerland)), Corinne Simeon(Novartis Institutes for BioMedical Research), Markus Streiff(Novartis Institutes for BioMedical Research), Trixie Wagner(Novartis (Switzerland)), Karl Welzenbach(Novartis Institutes for BioMedical Research), Frédéric J. Zécri(Novartis Institutes for BioMedical Research), Markus Zollinger(Novartis Institutes for BioMedical Research), Nigel G. Cooke(Novartis (Switzerland)), Eric Francotte(Novartis Institutes for BioMedical Research)
Cited by 150Open Access
Abstract
In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biologically active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol especially elaborated for phosphates of 1. Starting from the prochiral amino alcohol 1, racemic and enantiomerically pure phosphates of 1 were synthesized. Pure enantiomers were obtained after purification of a partially protected key intermediate on an enantioselective support. The absolute stereochemistry was determined by X-ray diffraction.
Related Papers
No related papers found
Powered by citation graph analysis